Pharmaron Beijing Co Ltd
SZSE:300759
Intrinsic Value
Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. [ Read More ]
The intrinsic value of one
Pharmaron Beijing Co Ltd
stock under the Base Case scenario is
31.24
CNY.
Compared to the current market price of 18.18 CNY,
Pharmaron Beijing Co Ltd
is
Undervalued by 42%.
Pharmaron Beijing Co Ltd's market capitalization is 32.2B CNY.
Pharmaron Beijing Co Ltd stock price is 18.18 CNY.
Pharmaron Beijing Co Ltd stock price (18.18 CNY) is 42% less than its Intrinsic Value (31.24 CNY).
Pharmaron Beijing Co Ltd stock (16.64 CNY) is 8% less than its price (18.18 CNY). Open DCF Valuation
Pharmaron Beijing Co Ltd stock price (18.18 CNY) is 60% less than its Relative Value (45.84 CNY). Open Relative Valuation
Pharmaron Beijing Co Ltd has upside potential of 64% compared to the average analyst price target.
Open Wall St Estimates
Pharmaron Beijing Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
Pharmaron Beijing Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 16% to 14%.
Pharmaron Beijing Co Ltd has positive three-year average ROIC (Return on Invested Capital): 11%. The company is efficient at using invested capital to generate operating income.
Pharmaron Beijing Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
Pharmaron Beijing Co Ltd's Revenue has grown by 12% over the past 12 months.
Pharmaron Beijing Co Ltd has positive Net Debt. This means that the company has more debt (9B CNY) than cash and short-term investments (7B CNY).
Pharmaron Beijing Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 15% to 8%.
Pharmaron Beijing Co Ltd has positive Net Income for the last twelve months.
Pharmaron Beijing Co Ltd has positive three-year average ROE (Return on Equity): 15%. The company is efficient at transforming stockholders' equity into net income.
Pharmaron Beijing Co Ltd's Revenue is forecast to grow at a rate of 13% per year over the next 3 years.
Pharmaron Beijing Co Ltd has positive Operating Income for the last twelve months.
Pharmaron Beijing Co Ltd has negative Free Cash Flow for the last twelve months.
Pharmaron Beijing Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.75.
Pharmaron Beijing Co Ltd has positive Gross Profit for the last twelve months.
Pharmaron Beijing Co Ltd's long-term assets (26B CNY) exceed its long-term liabilties (14B CNY).
Pharmaron Beijing Co Ltd's Revenue has been growing by an exceptional 31% per year for the last 3 years.
Pharmaron Beijing Co Ltd's Altman Z-Score is very high and is equal to 3.24.
Pharmaron Beijing Co Ltd's short-term assets (11B CNY) exceed its short-term liabilties (4B CNY).
Valuation Backtest
Pharmaron Beijing Co Ltd
Run backtest to discover the historical profit from buying and selling
Pharmaron Beijing Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Pharmaron Beijing Co Ltd
Balance Sheet Decomposition
Pharmaron Beijing Co Ltd
| Current Assets | 10.9B |
| Cash & Short-Term Investments | 6.6B |
| Receivables | 3B |
| Other Current Assets | 1.3B |
| Non-Current Assets | 15.6B |
| Long-Term Investments | 1B |
| PP&E | 10.1B |
| Intangibles | 3.6B |
| Other Non-Current Assets | 964.9m |
| Current Liabilities | 3.7B |
| Accounts Payable | 412.2m |
| Accrued Liabilities | 805.6m |
| Short-Term Debt | 577.1m |
| Other Current Liabilities | 1.9B |
| Non-Current Liabilities | 10.3B |
| Long-Term Debt | 8.8B |
| Other Non-Current Liabilities | 1.5B |
Earnings Waterfall
Pharmaron Beijing Co Ltd
|
Revenue
|
11.5B
CNY
|
|
Cost of Revenue
|
-7.4B
CNY
|
|
Gross Profit
|
4.1B
CNY
|
|
Operating Expenses
|
-2.3B
CNY
|
|
Operating Income
|
1.8B
CNY
|
|
Other Expenses
|
-184.2m
CNY
|
|
Net Income
|
1.6B
CNY
|
Free Cash Flow Analysis
Pharmaron Beijing Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Pharmaron Beijing Co Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Pharmaron Beijing Co Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Pharmaron Beijing Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Pharmaron Beijing Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Pharmaron Beijing Co Ltd
According to Wall Street analysts, the average 1-year price target for
Pharmaron Beijing Co Ltd
is 29.82 CNY
with a low forecast of 9.19 CNY and a high forecast of 42 CNY.
Shareholder Return
Price
Pharmaron Beijing Co Ltd
| Average Annual Return | 39.05% |
| Standard Deviation of Annual Returns | 70.65% |
| Max Drawdown | -82% |
| Market Capitalization | 32.2B CNY |
| Shares Outstanding | 1 786 732 206 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Pharmaron Beijing Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing and currently employs 14,923 full-time employees. The company went IPO on 2019-01-28. Pharmaron Beijing Co., Ltd. is a China-based company that provides research and manufacturing services throughout the discovery, development and manufacturing spectrum for small molecule drugs, cell therapies and gene therapies as well as providing testing services for medical devices and clinic research. The firm has four segments. The Laboratory Services segment includes laboratory chemistry, drug metabolism and pharmacokinetics/absorption, distribution, metabolism and excretion, biology, safety assessment and discovery of biologics services. The Clinical Development Services segment includes clinical research, site management organization, regulatory bioanalysis and radiolabelled sciences service. The Chemistry, Manufactory and Control Services segment includes process development and manufacturing, material science/pre-formulation, formulation development and manufacturing and analytical development and commercial manufacturing services. The firm also operates Others segment.
Contact
IPO
Employees
Officers
The intrinsic value of one
Pharmaron Beijing Co Ltd
stock under the Base Case scenario is
31.24
CNY.
Compared to the current market price of 18.18 CNY,
Pharmaron Beijing Co Ltd
is
Undervalued by 42%.
You don't have any saved screeners yet
